tbuckley/cabot-search huggingface dataset:
Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype
Authors: Clive R. Pullinger, Celeste Eng, Gerald Salen, Sarah Shefer, Ashok K. Batta, Sandra K. Erickson, Andrea Verhagen, Christopher R. Rivera, Sean J. Mulvihill, Mary J. Malloy, John P. Kane
Journal: Journal of Clinical Investigation (2002)

Bile acid synthesis plays a critical role in the maintenance of mammalian cholesterol homeostasis. The CYP7A1 gene encodes the enzyme cholesterol 7α-hydroxylase, which catalyzes the initial step in cholesterol catabolism and bile acid synthesis. We report here a new metabolic disorder presenting with hyperlipidemia caused by a homozygous deletion mutation in CYP7A1. The mutation leads to a frameshift (L413fsX414) that results in loss of the active site and enzyme function. High levels of LDL cholesterol were seen in three homozygous subjects. Analysis of a liver biopsy and stool from one of these subjects revealed double the normal hepatic cholesterol content, a markedly deficient rate of bile acid excretion, and evidence for upregulation of the alternative bile acid pathway. Two male subjects studied had hypertriglyceridemia and premature gallstone disease, and their LDL cholesterol levels were noticeably resistant to 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. One subject also had premature coronary and peripheral vascular disease. Study of the kindred, which is of English and Celtic background, revealed that individuals heterozygous for the mutation are also hyperlipidemic, indicating that this is a codominant disorder.
Renal clearance measured by iohexol identifies cirrhotic patients with normal creatinine at risk of serious adverse events
Authors: Carlos González-Alayón, Natalia Negrín-Mena, Sergio Luis-Lima, Miguel Moreno, Dalia Morales Arraez, Esteban Porrini, Enrique Quintero, Manuel Hernandez-Guerra
Journal: Journal of Hepatology (2020)
The Clinical Response of Rheumatic Fever and Acute Carditis to ACTH
Authors: Benedict F. Massell, Joseph E. Warren, George P. Sturgis, Buford Hall, Ernest Craige
Journal: New England Journal of Medicine (1950)

ResultsNearly all the important manifestations of rheumatic fever are represented by the 10 patients whose case reports have been summarized. At the time ACTH therapy was begun, 8 patients had definite fever, 7 had symptoms or signs — or both — referable to the joints, 3 had subcutaneous nodules, 1 had chorea, 9 had signs of valvular involvement, 4 had pericarditis, 4 were in congestive failure, and all but 1 had elevation of the erythrocyte sedimentation rate. It is also evident from the case reports that the majority of the patients suffered from severe rheumatic fever and a high . . .
Impartial investigations identify wayward walking
Authors: J Edwards, M Leandro, G Cambridge
Journal: Annals of the Rheumatic Diseases (2002)

Objectives: To obtain evidence for dose response and to extend evidence of safety and efficacy for B lymphocyte depletion in rheumatoid arthritis.Methods: Twenty two patients with rheumatoid arthritis received a total of 29 treatments with five different combinations of rituximab (RTX), cyclophosphamide (CP), and/or high dose prednisolone (PR) on an open basis as follows; cohort I: RTX 1400 mg/m 2 , CP 750×2+PR; cohort II: RTX 300-700 mg/m 2 , -CP±PR); cohort III: RTX 600-700 mg/m 2 , CP 750×2+PR; cohort IV: RTX 1200 mg/m 2 , CP 750×2-PR; cohort V: RTX 500 mg/m 2 , CP 750×2+PR.American College of Rheumatology (ACR) criteria of improvement at six months were chosen as the primary outcome measure.Disease activity scores and total duration of improvement and of B cytopenia were also recorded.Results: No major adverse events attributable to treatment were seen.ACR grades of improvement at six months were as follows: cohort I: ACR70×3, ACR50×2; cohort II: ACR20×1,
Cognocardiology
Authors: Rodney H. Falk
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OP0283 Validation of the Educational Needs Assessment Tool as a Generic Instrument for Rheumatic Diseases in 7 European Countries
Authors: M. Ndosi, A. Bremander, B. Hamnes, M. Horton, M. L. Kukkurainen, P. Machado, A. Marques, J. Meesters, T. Stamm, A. Tennant, J. D. L. Torre-Aboki, T. Vliet Vlieland, H. Zangi, J. Hill
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To validate the educational needs assessment tool (The ENAT) as a generic tool with which to assess the educational needs of patients with rheumatic diseases in European Countries. <h3>Methods</h3> The study followed a quantitative cross-sectional design. Participants comprised a convenience sample of patients from 7 European countries with each of the following diagnostic group: ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic sclerosis (SSc), systemic lupus erythematosus (SLE), osteoarthritis (OA) and fibromyalgia syndrome (FMS). Rasch analysis was used to assess the construct validity of the adapted ENATs and cross-cultural invariance. <h3>Results</h3> The sample comprised 3015 patients with mean (SD) age 52.6 (13.1), disease duration 13.7 (10.7) years, 1996 (66.2%) of which were female. Patient characteristics (stratified by diagnostic group) were comparable across countries except the educational background, which was variable. Initially, the data from each country and diagnostic group was fitted to the Rasch model separately, and then the pooled data from each diagnostic group. On each occasion the data were required to satisfy Rasch model expectations, after correction for local dependency by creating clusters of items known as teslets. The OA group was an exception as it only did so in country-specific datasets, not within the pooled data. There was no significant differential item functioning (DIF) by age, gender, disease duration or educational background, indicating that the ENAT works in the same way across different patient groups. Uniform cross-cultural DIF was present and this was accounted for by ‘splitting’ the testlets that were affected. Subsequently, DIF-adjusted conversion tables were calibrated, to enable parametric analyses fully adjusted for cross-cultural bias when comparison of multinational data is required. <h3>Conclusions</h3> The ENAT is a cross-culturally valid and a reliable tool, providing accurate estimation of educational needs of people with rheumatic diseases. Further research is required for its cross-cultural use in OA. <h3>Disclosure of Interest</h3> None Declared
AB0136 The effect of il-6 receptor antibody for the treatment of mch-lpr/lpr-ra1 mice that spontaneously developed ankylosing arthritis
Authors: T. Izumiyama, Y. Mori, S. Mori, K. Takeda, S. Horie, T. kodama, E. Itoi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> McH-lpr/lpr-RA1 (RA1) mice are new strain mice which spontaneously developed arthritis in ankle and finally leads to ankylosis.<sup>1</sup> There is no report that drug treatment has been applied to these mice. <h3>Objectives</h3> To examine the effect of mouse IL-6 receptor antibody MR16–1 for the treatment of RA-1 mice. <h3>Methods</h3> Male RA1 mice were randomly divided into treated and control groups. MR 16–1 was applied from 10 weeks of age for the treatment group. Saline was applied for the control group. The drug was administered every two weeks with the initial dose of 2 mg, then 0.5 mg. The effects were evaluated by histological synovitis score, <i>in vivo</i> imaging using ICG-encapsulated liposomes and the expression of serum SAA and IL-6. <h3>Results</h3> The tissue evaluation was carried out at 14 weeks, 17 weeks and 20 weeks of age. The histological score of treated groups were significantly improved compared with control group at every age. The interclass correlation coefficient was 0.771. <i>In vivo</i> imaging using ICG-encapsulated liposomes showed that significant signal decrease in treated groups at 14 weeks, but no significant difference was observed after 16 weeks. Blood SAA was significantly improved at 17 weeks of age. <h3>Conclusions</h3> IL-6 receptor antibody is effective for the treatment of ankylosing arthritis of RA1 mice. IL-6 might be a new potential target of treatment for ankylosing arthritis. <h3>Reference</h3> [1] Mori S, Tanda N, Ito MR, et al. Novel recombinant congenic mouse strain developing arthritis with enthesopathy. Pathol Int2008;58:407–414. <h3>Disclosure of Interest</h3> None declared
Fetal Infection in Chickenpox and Alastrim
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DERMOID CYSTS AND TERATOMAS OF THE MEDIASTINUM.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Smoking Cessation in Patients With HIV
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Differential Effects of Two Lots of Aroclor 1254 on Enzyme Induction, Thyroid Hormones, and Oxidative Stress
Authors: Deborah E. Burgin, Janet J. Diliberto, Ethel C. Derr-Yellin, Narayanan Kannan, Prasada R. S. Kodavanti, Linda S. Birnbaum
Journal: Environmental Health Perspectives (2001)

Aroclor 1254 is a commercial mixture of polychlorinated biphenyls (PCBs), which is defined as being 54% chlorine by weight. However, the congener composition varies from lot to lot. Two lots which have been used in toxicity studies, 124-191 and 6024 (AccuStandard), were analyzed for their congener composition. Lot 6024 has approximately 10 times the dioxin toxic equivalents (TEQ) of lot 124-191. The purpose of this study was to determine if the difference in the TEQ of the two lots explains the different in vivo responses seen on a weight basis. Male Long-Evans rats (70 days old) were treated orally with a single dose of 0-1,000 mg/kg of each lot. Hepatic ethoxy-, methoxy-, and pentoxyresorufin O-deethylase (EROD, MROD, and PROD, respectively) activities as well as serum thyroxine (T(4)) concentrations and measures of oxidative stress were determined 4 days after treatment. Results, on a weight basis, indicate that lot 6024 led to a greater induction of EROD, MROD, and PROD but not total T(4) reduction. The differences in TEQ between the lots explained the differential induction of EROD and MROD but did not account for the induction of PROD nor decreases in T(4). PROD induction is not due to dioxin-like congeners, whereas the decrease in serum T(4) levels may involve multiple mechanisms. Effects on the antioxidants ascorbic acid and uric acid were seen only at the highest mass dose for both lots and were not explained by the difference in TEQ. These results illustrate that the differences in the TEQ explain the differences in the strict dioxin-like effects (EROD, MROD induction), but the non-dioxin-like congeners cause other effects that are not associated with the aryl hydrocarbon receptor (e.g., PROD). In addition, supra-additive effects also occur in the mixture (T(4), oxidative stress). Thus, current results demonstrate that overall toxicity cannot be predicted on the basis of the TEQ values. It is also critical that the lot number is reported in studies conducted with Aroclor 1254 because the congener composition and therefore the effects observed can be very different.
Journal of Experimental Medicine, New York
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial
Authors: Robert Rosenstein, David Parra
Journal: The Lancet (2009)

Paul Ridker and colleagues1 conclude that reductions of LDL cholesterol and high-sensitivity C-reactive protein (hsCRP) are indicators of successful treatment with rosuvastatin. However, the JUPITER trial did not target specific concentrations of hsCRP or LDL cholesterol by means of a strategy of titration of rosuvastatin. Rather, it assessed a single dose versus placebo. No evidence was presented to suggest that adjusting statin doses to reach a particular concentration of hsCRP (or LDL cholesterol) would improve outcomes.
Gehirnpräparation mittels Zerfaserung;
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rotary fracture-dislocation of the cervical spine
Authors: O. E. Aufranc
Journal: JAMA (1969)

Dr. Arthur L. Boland: This was the first Massachusetts General Hospital admission for a 21-year-old college student who had a history of being involved in a car accident eight days before admission. The patient allegedly was thrown against the roof of a car in an accident and had been taken to a local hospital. Roentgenograms at the time of his admission were interpreted as normal. However, because of persistent neck pain with radiation to the top of the right shoulder and mid arm, the x-ray films were reevaluated and a fracture was noted. He was then transferred here for further care. There were no symptoms of numbness, tingling, or paresthesias. He gave no history of loss of consciousness or of injury other than to his neck. Medical history was noncontributory. Physical examination at the time of admission revealed a blood pressure of 120/80 mm Hg, pulse rate of 80 beats
Current Comment
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coagulase-negative staphylococcal bacteremia in the changing neonatal intensive care unit population. Is there an epidemic?
Authors: J. Freeman
Journal: JAMA (1987)

A fivefold increase in the number of cases of nosocomial coagulase-negative staphylococcal bacteremia was investigated in a neonatal intensive care unit between 1975 and 1982. This apparent outbreak was not the result of increased isolation of coagulase-negative staphylococci from blood cultures nor an increased frequency with which blood cultures were obtained. Rather, it was attributable to a dramatic increase in the overall probability that a positive blood culture would be interpreted as "bacteremia" as opposed to a contaminant by both physicians and infection control staff. Specifically, there had been a 62.3% increase in neonatal intensive care unit bed use by very-low-birth-weight (&lt;1000-g) infants between 1975 and 1982, and in both years, positive blood cultures were 3.8 times as likely to be perceived as clinically significant if obtained from such tiny infants. The growing number of very-low-birth-weight babies occupying neonatal intensive care unit beds, coupled with the observation that blood cultures positive for coagulase-negative staphylococci are almost four times as likely to be perceived as clinically significant if obtained from extremely premature infants, may account for the reported increase in nosocomial coagulase-negative staphylococcal bacteremia. (<i>JAMA</i>1987;258:2548-2552)
Editorial: Choice of a mild analgesic.
Journal: BMJ (1974)

who emigrate: it is not easy to see how they could be compelled to repay their loans before leaving and if no such way were devised there would be an added incentive to leave the country in order to escape this obligation-a wholly un- desirable effect.Overall, then, it seems that while there may be a case for discussing further the idea of supplementing, or even replacing, grants by loans, this is not going to be an easy way out of the current dilemma of too many